The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects

• Status: Completed
• Trial end date: 2001-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Gemphire Therapeutics, Inc.; NeuroBo Pharmaceuticals Inc.
• Treatments: Insulin

Criteria

Inclusion Criteria:

• Good health, as determined by medical history, physical examination, EKG and clinical laboratory assessments

• Males; and females of non-reproductive potential

• Obesity

• Non-diabetic

Exclusion Criteria:

• Use of any medication considered unacceptable by the clinical investigators during the 14-day period before the start of Day 1. Hormone Replacement Therapy is acceptable.

• Use of a lipid-lowering agent (niacin, fibrates, statin) during the 8 weeks before screening

• Use of any anti-diabetic medications

• Use of any steroid medications

• Donation of any blood or plasma product or participation in another study in the 30 days prior to Day 1

• If female, pregnant, lactating or of childbearing potential; and

• History of significant reaction to any fibrate lipid-lowering agent